<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36201126</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Feasibility and diagnostics of the Frontal Assessment Battery (FAB) in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>587</StartPage><EndPage>592</EndPage><MedlinePgn>587-592</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-022-06438-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The present study aimed at evaluating the diagnostic properties of the Frontal Assessment Battery (FAB) in non-demented ALS patients by addressing the Edinburgh Cognitive Behavioural ALS Screen (ECAS) as the gold standard, as well as by examining the association between its administrability and scores with motor-functional measures.</AbstractText><AbstractText Label="MATERIALS" NlmCategory="METHODS">N&#x2009;=&#x2009;348 consecutive patients were administered the ECAS and FAB. Disease severity (ALSFRS-R), duration, progression rate (&#x394;FS), and stages (via King's and Milano-Torino systems) were considered. Administrability rates and prevalence of below-cut-off FAB scores were compared across clinical stages; regression models allowed to test whether, net of the ECAS-Total, motor features predicted the probability of the FAB not being administrable and of a defective FAB score. Intrinsic and post-test diagnostics were explored against a combined defective ECAS-Executive and ECAS-Fluency scores.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">85.3% of patients managed to complete the FAB. FAB administrability rates decreased with advanced clinical stages, whereas the prevalence of below-cut-off FAB scores did not. The probability of the FAB not being administrable was predicted only by lower ALSFRS-R-bulbar and ALSFRS-R-upper-limb scores; no motor features, but the ECAS-Total, predicted a below-cut-off performance on the FAB. Raw and adjusted FAB scores&#xa0;showed high accuracy (AUC&#x2009;=&#x2009;.85 and .81, respectively) and good intrinsic and post-test properties.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The FAB is featured by optimal diagnostics for detecting executive deficits in ALS, provided that it can be administered according to its original, standardized procedure, and thus that patients have sufficiently spared motor abilities to complete the test.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aiello</LastName><ForeName>Edoardo Nicol&#xf2;</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>IRCCS Istituto Auxologico Italiano, Department of Neurology and Laboratory of Neuroscience, Piazzale Brescia 20, Milano, 20149, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PhD Program in Neuroscience, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Solca</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>IRCCS Istituto Auxologico Italiano, Department of Neurology and Laboratory of Neuroscience, Piazzale Brescia 20, Milano, 20149, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torre</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IRCCS Istituto Auxologico Italiano, Department of Neurology and Laboratory of Neuroscience, Piazzale Brescia 20, Milano, 20149, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carelli</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>IRCCS Istituto Auxologico Italiano, Department of Neurology and Laboratory of Neuroscience, Piazzale Brescia 20, Milano, 20149, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrucci</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Aldo Ravelli Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, International Medical School, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ASST Santi Paolo E Carlo, San Paolo University Hospital, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Ca' Granda Foundation Maggiore Policlinico Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Priori</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Aldo Ravelli Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, International Medical School, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ASST Santi Paolo E Carlo, San Paolo University Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verde</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>IRCCS Istituto Auxologico Italiano, Department of Neurology and Laboratory of Neuroscience, Piazzale Brescia 20, Milano, 20149, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, "Dino Ferrari Center", Universit&#xe0; Degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ticozzi</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>IRCCS Istituto Auxologico Italiano, Department of Neurology and Laboratory of Neuroscience, Piazzale Brescia 20, Milano, 20149, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, "Dino Ferrari Center", Universit&#xe0; Degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>IRCCS Istituto Auxologico Italiano, Department of Neurology and Laboratory of Neuroscience, Piazzale Brescia 20, Milano, 20149, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, "Dino Ferrari Center", Universit&#xe0; Degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Poletti</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4398-2051</Identifier><AffiliationInfo><Affiliation>IRCCS Istituto Auxologico Italiano, Department of Neurology and Laboratory of Neuroscience, Piazzale Brescia 20, Milano, 20149, Italy. b.poletti@auxologico.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Cognitive screening</Keyword><Keyword MajorTopicYN="N">Diagnostics</Keyword><Keyword MajorTopicYN="N">Executive</Keyword><Keyword MajorTopicYN="N">Frontal assessment battery</Keyword><Keyword MajorTopicYN="N">Psychometrics</Keyword></KeywordList><CoiStatement>V. S. received compensation for consulting services and/or speaking activities from the AveXis, Cytokinetics, Italfarmaco, Liquidweb S.r.l., and Novartis Pharma AG and receives or has received research support from the Italian Ministry of Health, AriSLA, and E-Rare Joint Transnational Call. He is on the Editorial Board of the <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i>, <i>European Neurology</i>, <i>American Journal of Neurodegenerative Diseases</i>, <i>Frontiers in Neurology</i>. B.P. received compensation for consulting services and/or speaking activities from the Liquidweb S.r.l. N. T. received compensation for consulting services from the Amylyx Pharmaceuticals and Zambon Biotech SA. He is an Associate Editor for the <i>Frontiers in Aging Neuroscience</i>. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>6</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36201126</ArticleId><ArticleId IdType="pmc">PMC9842552</ArticleId><ArticleId IdType="doi">10.1007/s10072-022-06438-5</ArticleId><ArticleId IdType="pii">10.1007/s10072-022-06438-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology. 2000;55:1621&#x2013;1626. doi: 10.1212/WNL.55.11.1621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.55.11.1621</ArticleId><ArticleId IdType="pubmed">11113214</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, Woolley S, Mclaughlin P, Snowden J, ... and Turner MR (2017) Amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotrophic Lateral Scler Frontotemporal Degener&#xa0;18:153-174</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremolizzo L, Ferrarese C, Appollonio I. Exploring limits of neuropsychological screening in ALS: the FAB problem. Amyotrophic Lateral Scler Frontotemporal Degener. 2013;14:157&#x2013;158. doi: 10.3109/21678421.2012.746990.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.746990</ArticleId><ArticleId IdType="pubmed">23286758</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon N, Goldstein LH. Screening for cognitive and behavioral change in amyotrophic lateral sclerosis/motor neuron disease: a systematic review of validated screening methods. Amyotrophic Lateral Scler Frontotemporal Degener. 2019;20:1&#x2013;11. doi: 10.1080/21678421.2018.1530264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1530264</ArticleId><ArticleId IdType="pubmed">30585510</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray D, Abrahams S. International evaluation of current practices in cognitive assessment for motor neurone disease. Br J Neurosci Nurs. 2022;18:38&#x2013;44. doi: 10.12968/bjnn.2022.18.1.38.</Citation><ArticleIdList><ArticleId IdType="doi">10.12968/bjnn.2022.18.1.38</ArticleId></ArticleIdList></Reference><Reference><Citation>Beswick E, Park E, Wong C, Mehta AR, Dakin R, Chandran S, ... and Pal S (2021) A systematic review of neuropsychiatric and cognitive assessments used in clinical trials for amyotrophic lateral sclerosis.&#xa0;J Neurol&#xa0;268:4510-4521</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8563523</ArticleId><ArticleId IdType="pubmed">32910255</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselt IK, Nijboer TC, Van Es MA. An overview of screening instruments for cognition and behavior in patients with ALS: selecting the appropriate tool for clinical practice. Amyotrophic Lateral Scler Frontotemporal Degener. 2020;21:324&#x2013;336. doi: 10.1080/21678421.2020.1732424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1732424</ArticleId><ArticleId IdType="pubmed">32157912</ArticleId></ArticleIdList></Reference><Reference><Citation>Taule T, S&#xf8;vik M, Lein RK, Wehling E, A&#xdf;mus J, Rekand T. Psychometric properties of cognitive assessment in amyotrophic lateral sclerosis: a systematic review. Patient Relat Outcome Meas. 2020;11:181. doi: 10.2147/PROM.S256828.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/PROM.S256828</ArticleId><ArticleId IdType="pmc">PMC7519807</ArticleId><ArticleId IdType="pubmed">33061727</ArticleId></ArticleIdList></Reference><Reference><Citation>Floris G, Borghero G, Chi&#xf2; A, Secchi L, Cannas A, Sardu C, ... and Marrosu MG (2012) Cognitive screening in patients with amyotrophic lateral sclerosis in early stages. Amyotrophic Lateral Scler&#xa0;13:95-101</Citation><ArticleIdList><ArticleId IdType="pubmed">21895509</ArticleId></ArticleIdList></Reference><Reference><Citation>Barulli MR, Fontana A, Panza F, Copetti M, Bruno S, Tursi M, ... and Logroscino G (2015) Frontal assessment battery for detecting executive dysfunction in amyotrophic lateral sclerosis without dementia: a retrospective observational study. BMJ Open&#xa0;5:e007069</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4563243</ArticleId><ArticleId IdType="pubmed">26338835</ArticleId></ArticleIdList></Reference><Reference><Citation>Raaphorst J, Beeldman E, Jaeger B, Schmand B, Van Den Berg LH, Weikamp JG, ... and De Haan RJ (2013) Is the Frontal Assessment Battery reliable in ALS patients? Amyotrophic Lateral Scler Frontotemporal Degener&#xa0;14:73-74</Citation><ArticleIdList><ArticleId IdType="pubmed">22889176</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborne RA, Sekhon R, Johnston W, Kalra S. Screening for frontal lobe and general cognitive impairment in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2014;336:191&#x2013;196. doi: 10.1016/j.jns.2013.10.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2013.10.038</ArticleId><ArticleId IdType="pubmed">24239183</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderploeg RD. Interview and testing: the data collection phase of neuropsychological evaluations. In: Vanderploeg RD, editor. Clinician&#x2019;s Guide to Neuropsychological Assessment. Lawrence Erlbaurn Associates; 2000. pp. 3&#x2013;38.</Citation></Reference><Reference><Citation>Oskarsson B, Quan D, Rollins YD, Neville HE, Ringel SP, Arciniegas DB. Using the Frontal Assessment Battery to identify executive function impairments in amyotrophic lateral sclerosis: a preliminary experience. Amyotroph Lateral Scler. 2010;11:244&#x2013;247. doi: 10.3109/17482960903059588.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903059588</ArticleId><ArticleId IdType="pubmed">19530013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn SW, Kim SH, Kim JE, Kim SM, Kim SH, Sung JJ, ... and Hong YH (2011) Frontal assessment battery to evaluate frontal lobe dysfunction in ALS patients. Canadian J Neurol Sci&#xa0;38:242-246</Citation><ArticleIdList><ArticleId IdType="pubmed">21320827</ArticleId></ArticleIdList></Reference><Reference><Citation>Terada T, Miyata J, Obi T, Kubota M, Yoshizumi M, Yamazaki K, ... and Murai T (2017) Frontal assessment battery and frontal atrophy in amyotrophic lateral sclerosis. Brain Behavior&#xa0;7:e00707</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5474710</ArticleId><ArticleId IdType="pubmed">28638712</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Moglia C, Canosa A, Manera U, Vasta R, Brunetti M, ... and Calvo A (2019) Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology&#xa0;93:e984-e994</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6745732</ArticleId><ArticleId IdType="pubmed">31409738</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. Amyotrophic Lateral Scler Frontotemporal Degener. 2014;15:9&#x2013;14. doi: 10.3109/21678421.2013.805784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.805784</ArticleId><ArticleId IdType="pubmed">23781974</ArticleId></ArticleIdList></Reference><Reference><Citation>Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S, ... and Abrahams S (2018) ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology&#xa0;91:e1370-e1380</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6177274</ArticleId><ArticleId IdType="pubmed">30209236</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti B, Solca F, Carelli L, Madotto F, Lafronza A, Faini A, ... and Silani V (2016) The validation of the Italian Edinburgh cognitive and behavioural ALS screen (ECAS). Amyotrophic Lateral Scler Frontotemporal Degener&#xa0;17:489-498</Citation><ArticleIdList><ArticleId IdType="pubmed">27219526</ArticleId></ArticleIdList></Reference><Reference><Citation>Appollonio I, Leone M, Isella V, Piamarta F, Consoli T, Villa ML, ... and Nichelli P (2005) The Frontal Assessment Battery (FAB): normative values in an Italian population sample. Neurol Sci&#xa0;26:108-116</Citation><ArticleIdList><ArticleId IdType="pubmed">15995827</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, ... and the BDNF Study Group (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci&#xa0;169:13-21</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura FCSHDH, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, ... and Hanafusa T (2006) Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS.&#xa0;Neurology&#xa0;66:265-267</Citation><ArticleIdList><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, ... and Al-Chalabi A (2012) A proposed staging system for amyotrophic lateral sclerosis.&#xa0;Brain&#xa0;135:847-852</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286327</ArticleId><ArticleId IdType="pubmed">22271664</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86:38&#x2013;44. doi: 10.1136/jnnp-2013-306589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-306589</ArticleId><ArticleId IdType="pubmed">24336810</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HY. Statistical notes for clinical researchers: assessing normal distribution (2) using skewness and kurtosis. Restor Dent Endod. 2013;38:52&#x2013;54. doi: 10.5395/rde.2013.38.1.52.</Citation><ArticleIdList><ArticleId IdType="doi">10.5395/rde.2013.38.1.52</ArticleId><ArticleId IdType="pmc">PMC3591587</ArticleId><ArticleId IdType="pubmed">23495371</ArticleId></ArticleIdList></Reference><Reference><Citation>Goksuluk D, Korkmaz S, Zararsiz G, Karaagaoglu AE. easyROC: an interactive web-tool for ROC curve analysis using R language environment. The R Journal. 2016;8:213&#x2013;230. doi: 10.32614/RJ-2016-042.</Citation><ArticleIdList><ArticleId IdType="doi">10.32614/RJ-2016-042</ArticleId></ArticleIdList></Reference><Reference><Citation>Larner AJ. Introduction to Cognitive Screening Instruments: Rationale and Desiderata. In: Larner AJ, editor. Cognitive screening instruments: a practical approach. Springer; 2017. pp. 3&#x2013;14.</Citation></Reference><Reference><Citation>Woolley SC, York MK, Moore DH, Strutt AM, Murphy J, Schulz PE, Katz JS. Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS&#x2122;) Amyotroph Lateral Scler. 2010;11:303&#x2013;311. doi: 10.3109/17482961003727954.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482961003727954</ArticleId><ArticleId IdType="pubmed">20433413</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiello EN, Esposito A, Gramegna C, Gazzaniga V, Zago S, Difonzo T, ... and Bolognini N (2022) The Frontal Assessment Battery (FAB) and its sub-scales: validation and updated normative data in an Italian population sample. Neurol Sci&#xa0;43:979-984</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8789707</ArticleId><ArticleId IdType="pubmed">34184168</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>